Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34 + cell content

C. H. Weaver, J. Potz, J. Redmond, K. Tauer, Lee Schwartzberg, P. Kaywin, R. Drapkin, B. Grant, P. Unger, C. Allen, K. Longin, B. Zhen, B. Hazelton, C. D. Buckner

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Engraftment kinetics after high-dose chemotherapy (HDC) were evaluated in patients receiving autologous peripheral blood stem cell (PBSC) infusions with a low CD34 + cell content. Forty-eight patients were infused with < 2.5 x 10 6 CD34 + cells/kg; 36 because of poor harvests and 12 because they electively received only a fraction of their harvested cells. A median of 2.12 x 10 6 CD34 + cells/kg (range, 1.17-2.48) were infused following one of seven different HDC regimens. All patients achieved absolute neutrophil counts ≤ 0.5 x 10 9 /l at a median of day 11 (range, 9-16). Forty-seven patients achieved platelet counts ≤ 20 x 10 9 /l at a median of day 14 (range, 8-250). Nine of 47 (19%) had platelet recovery after day 21, 4/47 (9%) after day 100 and one died on day 240 without platelet recovery. Twenty-six patients (54%) died of progressive disease in 51-762 days; 22 (46%) are alive at a median of 450 days (range, 94-1844), 17 (35%) of whom are surviving disease-free at a median of 494 days (range, 55-1263). No patient died as a direct consequence of low blood cell counts. These data demonstrate that PBSC products containing 1.17-2.48 x 10 6 CD34 + cells/kg resulted in relatively prompt neutrophil recovery in all patients but approximately 10% had delayed platelet recovery.

Original languageEnglish (US)
Pages (from-to)1103-1110
Number of pages8
JournalBone Marrow Transplantation
Volume19
Issue number11
DOIs
StatePublished - Jun 1 1997

Fingerprint

Blood Platelets
Therapeutics
Neutrophils
Drug Therapy
Blood Cell Count
Peripheral Blood Stem Cells
Platelet Count

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34 + cell content . / Weaver, C. H.; Potz, J.; Redmond, J.; Tauer, K.; Schwartzberg, Lee; Kaywin, P.; Drapkin, R.; Grant, B.; Unger, P.; Allen, C.; Longin, K.; Zhen, B.; Hazelton, B.; Buckner, C. D.

In: Bone Marrow Transplantation, Vol. 19, No. 11, 01.06.1997, p. 1103-1110.

Research output: Contribution to journalArticle

Weaver, CH, Potz, J, Redmond, J, Tauer, K, Schwartzberg, L, Kaywin, P, Drapkin, R, Grant, B, Unger, P, Allen, C, Longin, K, Zhen, B, Hazelton, B & Buckner, CD 1997, ' Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34 + cell content ', Bone Marrow Transplantation, vol. 19, no. 11, pp. 1103-1110. https://doi.org/10.1038/sj.bmt.1700808
Weaver, C. H. ; Potz, J. ; Redmond, J. ; Tauer, K. ; Schwartzberg, Lee ; Kaywin, P. ; Drapkin, R. ; Grant, B. ; Unger, P. ; Allen, C. ; Longin, K. ; Zhen, B. ; Hazelton, B. ; Buckner, C. D. / Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34 + cell content In: Bone Marrow Transplantation. 1997 ; Vol. 19, No. 11. pp. 1103-1110.
@article{571ae263c0d44cca98a29ff8fe7af6ef,
title = "Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34 + cell content",
abstract = "Engraftment kinetics after high-dose chemotherapy (HDC) were evaluated in patients receiving autologous peripheral blood stem cell (PBSC) infusions with a low CD34 + cell content. Forty-eight patients were infused with < 2.5 x 10 6 CD34 + cells/kg; 36 because of poor harvests and 12 because they electively received only a fraction of their harvested cells. A median of 2.12 x 10 6 CD34 + cells/kg (range, 1.17-2.48) were infused following one of seven different HDC regimens. All patients achieved absolute neutrophil counts ≤ 0.5 x 10 9 /l at a median of day 11 (range, 9-16). Forty-seven patients achieved platelet counts ≤ 20 x 10 9 /l at a median of day 14 (range, 8-250). Nine of 47 (19{\%}) had platelet recovery after day 21, 4/47 (9{\%}) after day 100 and one died on day 240 without platelet recovery. Twenty-six patients (54{\%}) died of progressive disease in 51-762 days; 22 (46{\%}) are alive at a median of 450 days (range, 94-1844), 17 (35{\%}) of whom are surviving disease-free at a median of 494 days (range, 55-1263). No patient died as a direct consequence of low blood cell counts. These data demonstrate that PBSC products containing 1.17-2.48 x 10 6 CD34 + cells/kg resulted in relatively prompt neutrophil recovery in all patients but approximately 10{\%} had delayed platelet recovery.",
author = "Weaver, {C. H.} and J. Potz and J. Redmond and K. Tauer and Lee Schwartzberg and P. Kaywin and R. Drapkin and B. Grant and P. Unger and C. Allen and K. Longin and B. Zhen and B. Hazelton and Buckner, {C. D.}",
year = "1997",
month = "6",
day = "1",
doi = "10.1038/sj.bmt.1700808",
language = "English (US)",
volume = "19",
pages = "1103--1110",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34 + cell content

AU - Weaver, C. H.

AU - Potz, J.

AU - Redmond, J.

AU - Tauer, K.

AU - Schwartzberg, Lee

AU - Kaywin, P.

AU - Drapkin, R.

AU - Grant, B.

AU - Unger, P.

AU - Allen, C.

AU - Longin, K.

AU - Zhen, B.

AU - Hazelton, B.

AU - Buckner, C. D.

PY - 1997/6/1

Y1 - 1997/6/1

N2 - Engraftment kinetics after high-dose chemotherapy (HDC) were evaluated in patients receiving autologous peripheral blood stem cell (PBSC) infusions with a low CD34 + cell content. Forty-eight patients were infused with < 2.5 x 10 6 CD34 + cells/kg; 36 because of poor harvests and 12 because they electively received only a fraction of their harvested cells. A median of 2.12 x 10 6 CD34 + cells/kg (range, 1.17-2.48) were infused following one of seven different HDC regimens. All patients achieved absolute neutrophil counts ≤ 0.5 x 10 9 /l at a median of day 11 (range, 9-16). Forty-seven patients achieved platelet counts ≤ 20 x 10 9 /l at a median of day 14 (range, 8-250). Nine of 47 (19%) had platelet recovery after day 21, 4/47 (9%) after day 100 and one died on day 240 without platelet recovery. Twenty-six patients (54%) died of progressive disease in 51-762 days; 22 (46%) are alive at a median of 450 days (range, 94-1844), 17 (35%) of whom are surviving disease-free at a median of 494 days (range, 55-1263). No patient died as a direct consequence of low blood cell counts. These data demonstrate that PBSC products containing 1.17-2.48 x 10 6 CD34 + cells/kg resulted in relatively prompt neutrophil recovery in all patients but approximately 10% had delayed platelet recovery.

AB - Engraftment kinetics after high-dose chemotherapy (HDC) were evaluated in patients receiving autologous peripheral blood stem cell (PBSC) infusions with a low CD34 + cell content. Forty-eight patients were infused with < 2.5 x 10 6 CD34 + cells/kg; 36 because of poor harvests and 12 because they electively received only a fraction of their harvested cells. A median of 2.12 x 10 6 CD34 + cells/kg (range, 1.17-2.48) were infused following one of seven different HDC regimens. All patients achieved absolute neutrophil counts ≤ 0.5 x 10 9 /l at a median of day 11 (range, 9-16). Forty-seven patients achieved platelet counts ≤ 20 x 10 9 /l at a median of day 14 (range, 8-250). Nine of 47 (19%) had platelet recovery after day 21, 4/47 (9%) after day 100 and one died on day 240 without platelet recovery. Twenty-six patients (54%) died of progressive disease in 51-762 days; 22 (46%) are alive at a median of 450 days (range, 94-1844), 17 (35%) of whom are surviving disease-free at a median of 494 days (range, 55-1263). No patient died as a direct consequence of low blood cell counts. These data demonstrate that PBSC products containing 1.17-2.48 x 10 6 CD34 + cells/kg resulted in relatively prompt neutrophil recovery in all patients but approximately 10% had delayed platelet recovery.

UR - http://www.scopus.com/inward/record.url?scp=0030908074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030908074&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1700808

DO - 10.1038/sj.bmt.1700808

M3 - Article

VL - 19

SP - 1103

EP - 1110

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 11

ER -